U-47700

6Node page

what any key link opens

psx:substance/u-47700/value/timeline/insufflated/resolution@1

valuereferenced by edges — no row of its own

derived from · upstream

derived_fromtimeline · insufflated · resolutionpsx:substance/u-47700/proposal/timeline/ae813e81-ff4d-4092-aa24-ae4f3d575ea5

feeds · downstream

none recorded

psx:substance/u-47700/value/timeline/insufflated/resolution@1
└─ derived_from  proposal/timeline/ae813e81-ff4d-4092-aa24-ae4f3d575ea5  timeline · insufflated · resolution

indented by distance from this node, not by parentage

1Provenance card

the boundary, as counts

Sources

2923 with DOI

3 strong · 12 moderate · 14 weak

Compilations

12026-05-08T13:29:43.706Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

28last ruled 2026-06-04

0 awaiting a ruling

Issued documents

42026-10-19T20:34:25.337Z

notice · info card · emergency

Searches

182 with no results

queries and counts on the build

Claims checked

1584 supported

4 supported · 154 not

Correspondence

0received

consent field ships in Phase 4

Edges

404

derivations recorded for this entity

Complete over 29 sources, 1 compilation, and 28 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/u-47700/archive

2Build

one panel per compilation run

generation run 2026-05-08

70 min completedmodel pipeline-v5plan not recordedrun/b9562ed2…

Selection

results seen97

selected by the model40

consumed as sources29

Verification

claims checked158

supported2

partially supported2

not supported1

inconclusive153

record
seen / partial
working

The model's own caveats

sparse_evidence
structural_inference
safety_data_unverified

Reproduce

inputs: 29 source keys (listed under Sources)
plan: not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model: pipeline-v5
streams: none — agent transcripts are persisted from 2026-09 onward

18 searches — query, source, results, what was kept and why

18 searches for this run
#	source	query	seen	kept	rationale
1	PubChem	U-47700	1	1	Primary chemical identity verification
2	PubMed	U-47700 forensic postmortem blood concentration fatality	7	7	All provide key postmortem toxicology data for U-47700
3	ClinicalTrials.gov · absence	U-47700	0	0	Expected — U-47700 is a Schedule I controlled substance with no approved therapeutic use
4	PubMed	U-47700 overdose death case report toxicology	5	5	Direct case reports and forensic series on U-47700 fatalities
5	PubMed	U-47700 opioid pharmacology receptor binding	5	5	All directly relevant to U-47700 pharmacology and receptor binding
6	OpenAlex	U-47700 synthetic opioid pharmacology toxicology	10	3	Highly cited reviews with substantive U-47700 coverage
7	Web	U-47700 Ki binding affinity mu opioid receptor nM radioligand	10	1	Key pharmacological data points
8	PubMed	U-47700 analytical method detection urine blood screening	5	4	All provide validated analytical methods and metabolic data
9	Web	U-47700 DEA Schedule I emergency scheduling 2016 Federal Register	10	3	Primary regulatory documentation
10	UNODC	U-47700 substance details	1	1	Verified chemical identity and international scheduling
11	ClinicalTrials.gov · absence	U-47700	0	0	Confirms absence of clinical trial program
12	Web	U-47700 legal status UK Canada Australia New Zealand	10	3	International scheduling documentation
13	PubMed	U-47700 pharmacodynamics pharmacokinetics rat Ki binding	1	1	Primary quantitative PK/PD source with binding affinity data
14	Web	U-47700 Szmuszkovicz Upjohn patent 1978	10	1	Primary discovery documentation
15	Web	U-47700 CYP3A4 CYP2B6 FMO3 metabolism N-demethylation human liver microsomes	10	2	CYP enzyme identification for metabolism section
16	PubMed	U-47700 synthesis Upjohn benzamide opioid history 1970s	1	1	Definitive review paper; covers >40 year history
17	Web	U-47700 Prince death opioid toxicology 2016	10	1	Significant public health event linked to U-47700
18	CDC MMWR	U-47700 deaths fentanyl analogs 10 states 2016	1	1	Key epidemiological data source

158 claims by section — every cited sentence, checked against its source

safety46 · 2 ok

Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
A multi-drug fatality combining 3-fluorophenmetrazine, U-47700, amitriptyline, methamphetamine, and two designer benzodiazepines (flubromazolam, delorazepam).supported
Polydrug fatality case involving flubromazolam and delorazepam among other NPS. Cause of death: multiple drug toxicity. bkx060
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Benzodiazepines: Multiple fatal cases document co-ingestion of designer benzodiazepines (flubromazolam, diclazepam) and classical benzodiazepines (alprazolam) with U-47700. Benzodiazepines augment respiratory depression through GABAergic potentiation of brainstem depression. This combination is documented as directly lethal.supported
Polydrug fatality case involving flubromazolam and delorazepam among other NPS. Cause of death: multiple drug toxicity. bkx060
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →

pharmacology24 · 1 ok

Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — not_supportednot supportedworking →
Full MOR agonism has been confirmed by GTPγS functional assay, where U-47700 produces maximal stimulation comparable to reference MOR agonists (DAMGO, fentanyl)partially supported
Morphine used as reference: butyrylfentanyl, U-47700, and MT-45 have nM affinities at MOR-1, less potent than morphine at MOR, much weaker at DOR and KOR. Morphine MOR potency reference in GTPγS assay. j.neuropharm.2017.08.016
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →

history22 · 0 ok

Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →

pharmacokinetic-detail16 · 0 ok

Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

receptor-pharmacology12 · 0 ok

Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

summary12 · 1 ok

Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
It functions as a full MOR agonist through canonical Gαi/o signaling, confirmed by GTPγS functional assays and complete reversal of all effects by naloxone.partially supported
Morphine used as reference: butyrylfentanyl, U-47700, and MT-45 have nM affinities at MOR-1, less potent than morphine at MOR, much weaker at DOR and KOR. Morphine MOR potency reference in GTPγS assay. j.neuropharm.2017.08.016
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →

chemistry10 · 0 ok

Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →

comparative-pharmacology8 · 0 ok

Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

neuroscience6 · 0 ok

Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →

clinical-evidence2 · 0 ok

Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →

3Sources

29 consumed · sorted by year · feeds = sections resting on it

Sources 1 to 30
year	source	tier	status	feeds
2025	Rat-to-human PBPK model of U-47700: Unveiling pharmacokinetic risks of a synthetic opioid through interspecies extrapolationZhong L, Li L, He Q, Zhu X, Xiang P, Xiang X, Yan H · Toxicology and Applied Pharmacologydoi:10.1016/j.taap.2025.117352	moderate	consumed	2 sections
2024	Clinical Pharmacokinetics and Pharmacodynamics of NaloxoneSaari TI, Strang J, Dale O · Clinical Pharmacokineticsdoi:10.1007/s40262-024-01355-6	strong	consumed	1 section
2023	Development of a vaccine against the synthetic opioid U-47700Park H, Lin M, Zhou J, Eubanks LM, Zhou B, Janda KD · Frontiers in Pharmacologydoi:10.3389/fphar.2023.1219985	moderate	consumed	3 sections
2023	In silico characterization of ligand-receptor interactions for U-47700, N,N-didesmethyl-U-47700, U-50488 at mu- and kappa-opioid receptorsLaus A, Kumar A, Caboni P, De Luca MA, Baumann MH, Pieroni E, Tocco G · Archiv der Pharmaziedoi:10.1002/ardp.202300256	moderate	consumed	1 section
2022	Characterization of recent non-fentanyl synthetic opioids via three different in vitro mu-opioid receptor activation assaysVandeputte MM, Persson M, Walther D, Vikingsson S, Kronstrand R, Baumann MH, Gren H, Stove CP · Archives of Toxicologydoi:10.1007/s00204-021-03207-9	moderate	consumed	2 sections
2020	Challenges Related to Three Cases of Fatal Intoxication to Multiple Novel Synthetic OpioidsGarneau B, Desharnais B, Beauchamp-Dore A, Lavallee C, Mireault P, Lajeunesse A · Journal of Analytical Toxicologydoi:10.1093/jat/bkz018	weak	consumed	1 section
2020	DARK Classics in Chemical Neuroscience: U-47700Kyei-Baffour K, Lindsley CW · ACS Chemical Neurosciencedoi:10.1021/acschemneuro.0c00330	moderate	consumed	4 sections
2020	Designer drugs: mechanism of action and adverse effectsLuethi D, Liechti ME · Archives of Toxicologydoi:10.1007/s00204-020-02693-7	strong	consumed	1 section
2020	Multiplex detection of 14 fentanyl analogues and U-47700 in biological samples: Application to a panel of French hospitalized patientsJung J, Kolodziej A, Pape E, Bisch M, Javot L, Gibaja V, Jouzeau JY, Scala-Bertola J, Gambier N · Forensic Science Internationaldoi:10.1016/j.forsciint.2020.110437	moderate	consumed	1 section
2020	Pharmacodynamics and pharmacokinetics of the novel synthetic opioid, U-47700, in male ratsTruver MT, Smith CR, Garibay N, Kopajtic TA, Swortwood MJ, Baumann MH · Neuropharmacologydoi:10.1016/j.neuropharm.2020.108195	moderate	consumed	7 sections
2019	Case report: relevance of metabolite identification to detect new synthetic opioid intoxications illustrated by U-47700Richeval C, Gaulier JM, Romeuf L, Allorge D, Gaillard Y · International Journal of Legal Medicinedoi:10.1007/s00414-018-1969-3	weak	consumed	2 sections
2019	Postmortem concentrations of the synthetic opioid U-47700 in 26 fatalities associated with the drugFels H, Lottner-Nau S, Sax T, Roider G, Graw M, Auwaerter V, Musshoff F · Forensic Science Internationaldoi:10.1016/j.forsciint.2019.04.010	weak	consumed	3 sections
2019	To Test or Not To Test?: The Value of Toxicology in a Delayed Overdose DeathWalsh EE, Shoff EN, Zaney ME, Hime GW, Garavan F, Boland DM · Journal of Forensic Sciencesdoi:10.1111/1556-4029.13822	weak	consumed	1 section
2019	Toxic lifespan of the synthetic opioid U-47,700 in Finland verified by re-analysis of UPLC-TOF-MS dataKriikku P, Pelander A, Rasanen I, Ojanpera I · Forensic Science Internationaldoi:10.1016/j.forsciint.2019.04.030	weak	consumed	2 sections
2018	Analysis of fentanyl analogs and novel synthetic opioids in blood, serum/plasma, and urine in forensic caseworkMoody MT, Diaz S, Shah P, Papsun D, Logan BK · Drug Testing and Analysisdoi:10.1002/dta.2393	moderate	consumed	1 section
2018	Another fatal case related to the recreational abuse of U-47700Strehmel N, Dumpelmann D, Vejmelka E, Strehmel V, Roscher S, Scholtis S, Tsokos M · Forensic Science, Medicine, and Pathologydoi:10.1007/s12024-018-0018-3	weak	consumed	3 sections
2018	Metabolism of novel opioid agonists U-47700 and U-49900 using human liver microsomes with confirmation in authentic urine specimens from drug usersKrotulski AJ, Mohr ALA, Papsun DM, Logan BK · Drug Testing and Analysisdoi:10.1002/dta.2228	moderate	consumed	2 sections
2018	Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplaceBaumann MH, Majumdar S, Le Rouzic V, et al. · Neuropharmacologydoi:10.1016/j.neuropharm.2017.08.016	moderate	consumed	3 sections
2017	A Fatality Related to the Synthetic Opioid U-47700: Postmortem Concentration DistributionMcIntyre IM, Gary RD, Joseph S, Stabley R · Journal of Analytical Toxicologydoi:10.1093/jat/bkw124	weak	consumed	1 section
2017	An Expanding World of Novel Psychoactive Substances: OpioidsZawilska JB · Frontiers in Psychiatrydoi:10.3389/fpsyt.2017.00110	strong	consumed	4 sections
2017	Canada Gazette: Regulations Amending Schedule I to the Controlled Drugs and Substances Act (U-47700)Health Canadaurl:05303be8251da6e6	weak	consumed	cited only
2017	Circular 008/2017: A change to the Misuse of Drugs Act 1971 to control U-47700UK Home Officeurl:2f5b38eeb1243fa6	weak	consumed	cited only
2017	Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700 - 10 States, July-December 2016.O'Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden RM · MMWR. Morbidity and mortality weekly reportdoi:10.15585/mmwr.mm6643e1	moderate	consumed	1 section
2017	Multiple Drug-Toxicity Involving Novel Psychoactive Substances, 3-Fluorophenmetrazine and U-47700Ellefsen KN, Taylor EA, Simmons P, Willoughby V, Hall BJ · Journal of Analytical Toxicologydoi:10.1093/jat/bkx060	weak	consumed	1 section
2017	Near death from a novel synthetic opioid labeled U-47700: emergence of a new opioid classSchneir A, Metushi IG, Sloane C, Benaron DJ, Fitzgerald RL · Clinical Toxicologydoi:10.1080/15563650.2016.1209764	weak	consumed	1 section
2017	UNODC Substance Details: U-47700 (CID 237db0fd)UNODC Laboratory and Scientific Sectionurl:3fdc70b47ed3951e	weak	consumed	cited only
2016	Analysis of Novel Synthetic Opioids U-47700, U-50488 and Furanyl Fentanyl by LC-MS/MS in Postmortem CaseworkMohr AL, Friscia M, Papsun D, Kacinko SL, Buzby D, Logan BK · Journal of Analytical Toxicologypmid:27590036	weak	consumed	2 sections
2016	DEA Schedules Deadly Synthetic Drug U-47700 - Press ReleaseDrug Enforcement Administrationurl:45a13c74420c2964	weak	consumed	cited only
2016	Schedules of Controlled Substances: Temporary Placement of U-47700 Into Schedule I. Final orderDEA Administrator · Federal Registerpmid:27905978	moderate	consumed	1 section
—	Searched ClinicalTrials.gov for "U-47700" — no resultsabsence		no results	—

Show all 31 sources — 1 more

Sources 31 to 31
year	source	tier	status	feeds
—	Searched ClinicalTrials.gov for "U-47700" — no resultsabsence		no results	—

4Docket

one filing per activity — decisions, correspondence, reports

0012026-05-08revisionRevision 1
Initial LLM generation (v5 pipeline, wiki, prose phase)
psx:substance/u-47700/version/1
0022026-06-04proposal26 value proposals approved together
one review action inferred from a shared reviewer and instant — the graph records one activity per proposal
26 items in this filing
- contraindication · other
- contraindication · hepatic
- contraindication · other
- contraindication · pregnancy_breastfeeding
- contraindication · other
- dose_tier · threshold
- dose_tier · light
- dose_tier · common
- dose_tier · strong
- dose_tier · heavy
- timeline · insufflated · onset
- timeline · insufflated · come_up
- timeline · insufflated · peak
- timeline · insufflated · resolution
- timeline · insufflated · afterglow
- toxicity
- dependence · full
- withdrawal
- tolerance
- dosage · insufflated
- duration · insufflated · onset
- duration · insufflated · come_up
- duration · insufflated · peak
- duration · insufflated · total
- duration · insufflated · aftereffects
psx:substance/u-47700/proposal/contraindication/5336b6ce-a858-4d68-a027-b309adc00ae3
0032026-06-04publicationPublication — backfill
psx:substance/u-47700/pub/34b1532c-3460-4f78-ba6b-65cf0090b547

5Issued documents

what the notice, info card and emergency page said, by hash

Issued documents
document	content hash	issued	from version	superseded
info_card	f4a704e0ac55e6b5c7d54f28…	2026-10-19 20:34	Revision 1	current
emergency	f85b2d2362c98030e2585598…	2026-09-04 04:32	Revision 1	current
info_card	0335bca422f8cbf5bd54828c…	2026-09-04 04:32	Revision 1	superseded2026-10-19
notice	de80e261c2b4a6c467864993…	2026-09-04 04:32	Revision 1	current

U-47700

6Node page

derived from · upstream

feeds · downstream

1Provenance card

2Build

generation run 2026-05-08

research→

draft→

audit→

verify→

simplify→

publish

Selection

Verification

The model's own caveats

Reproduce

3Sources

4Docket

5Issued documents

research

draft

audit

verify

simplify